

# celerion

**Translating Science to  
Medicine**

Celerion is a market leader in early clinical research, supporting clients around the world. We interviewed Bruce Morimoto PhD, Executive Director of Applied Translational Medicine at the firm to talk us through its service offering.

Celerion has been awarded Best Translational Clinical Pharmacology Company, recognized for their innovative approach to translating science to medicine. The awards panels based their decision on a number of factors including leadership in innovation, excellence in products and services, success stories and client testimonials.

Celerion is a global contract research organization specialising in early clinical studies. Serving clients of all sizes in the pharmaceutical and biotechnology industries, the firm focuses on clinical pharmacology Phase I and II trials.

*"The company's focus is on translating science into medicine via innovative strategies to generate key data very early to enable clients' go/no-go decisions in drug development. With a large global clinical capacity of more than 600 beds (24 in-hospital), efficient bioanalytical laboratories and experienced scientific staff, the firm offers one of the most experienced clinical pharmacology research networks in the industry."*

Working in such a vital industry means that the firm has to be vigilant and ensure that every trial is conducted to the highest possible standard. Dr. Morimoto outlines the firm's approach to achieving this.

*"Early clinical trials are a vital part of the pharmaceutical and biotechnical industries, as without them drugs cannot be approved. With such an important role we work diligently to ensure that our trials are safe and provide accurate results."*

*"The various governing bodies which regulate our industry provide guidelines and legislation, which we follow to the letter, as well as implementing our own standard operating procedures, which are the by-product of our many years of experience working in this field."*

Dr. Morimoto shared that "our staff are a key part of our business, and we offer a supportive internal culture. We firmly believe that our mission permeates from the top, and as such our leadership team works hard to ensure that every member of staff works as a team."

Technology is the key differentiator for Celerion, as Dr. Morimoto is keen to emphasize.

"Celerion is constantly innovating, creating and utilizing technology to benefit our clients. For instance, Clinquick®, is a totally unique electronic data acquisition platform that captures data directly from the clinic, minimizing human error and ensuring quality and speed. This validated system is one of the few truly source-free systems in the space and has been included in hundreds of clinical trial submissions and the subject of many regulatory audits over its decades-old lifetime."

"Another recent development is our remote global access service, Celexus®, an interactive portal where clients can view and analyze their clinical trial results no matter where they are in the world. Celexus is a custom tool created at Celerion specifically so our clients can evaluate a wide range of variables, including adverse events, clinical and bioanalytical data, and assess trends in real time. This innovation provides pharmacologists the ability to make informed decisions faster to maximize their study designs and ultimately speed development of new products."

In recent years the clinical trials market has changed dramatically. Although smaller pharmaceutical firms have always had to rely on outsourcing, larger firms have come to embrace outsourcing as a model for conducting clinical trials. It is this that has helped Celerion to grow and become a leader in this field, according to Dr. Morimoto, who added that despite the success the firm has seen in recent years it has no plans to rest on its laurels.

"The future looks bright for Celerion as we aim to move into a new market and expand our service offering. At the beginning of this year we acquired Assign Clinical Research, an Austria based company which conducts specialized clinical studies across a broad range of therapeutic areas with a particular focus in oncology, vaccines, cancer immunotherapy, personalized medicine and autoimmune disorders. This adds to the already existing capabilities Celerion

offers via hospital-embedded clinical pharmacology units (CPUs) in both South Korea and Singapore for early phase research."

"Our global growth and strategic focus in early clinical research supports our clients' needs to translate science and the discovery and early safety data from preclinical studies, into the first human medical applications of new chemical and molecular entities."

"Progressing into early patient studies in Phase II now demonstrates Celerion's strengthened service offerings for clients who need to reach a faster go/no-go development decision on new drug candidates. This new market brings opportunity to both Celerion and our clients and we look forward to the challenge!"

Company: Celerion  
Website: <https://celerion.com/>

